SCHEMBL2249290

SCHEMBL2249290

O=C(O)c1cccc(OCc2ccc(CN3CCOCC3)cc2)c1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
HIF1A Q16665 1/20 0.46
EPAS1 Q99814 1/20 0.46
CRBN Q96SW2 2/20 0.45
DDB1 Q16531 1/20 0.45
HTT P42858 2/20 0.45
TP53 P04637 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
TNF P01375 1/20 0.44
IL1B P01584 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2248485 0.90 ALDH1A1 (0.54) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL2250455 0.88 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2MAPTKDM4ELMNA
SCHEMBL2252009 0.86 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2KDM4ELMNANPC1
SCHEMBL2250404 0.83 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL2248969 0.79 ENPP2 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL1097820 0.79 PTGER1 (0.53) ALDH1A1KDM4EHTTTP53
SCHEMBL1097870 0.78 FOLH1 (0.62) ALDH1A1MEN1KMT2AMAPTMAPK1
Morpholine SCHEMBL27899076 0.77 HPD (0.45) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL2250512 0.77 FOLH1 (0.51) SMN1; SMN2MAPTNPC1RAB9AHTT
Morpholine SCHEMBL27881763 0.76 HPD (0.44) ALDH1A1KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4289838-A2 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2023-12-13 EP disclosed
EP-3599236-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2023-08-23 EP disclosed
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2022-12-29 US disclosed
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2022-08-16 US disclosed
US-20200231567-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2020-07-23 US disclosed
US-10669257-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2020-06-02 US disclosed
EP-3599236-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2020-01-29 EP disclosed
EP-3202460-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2019-06-12 EP disclosed
US-20190135780-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2019-05-09 US disclosed
EP-3106460-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2019-04-10 EP disclosed
US-20160159768-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2016-06-09 US disclosed
US-9309219-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2016-04-12 US disclosed
CN-104693193-A Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2015-06-10 CN disclosed
CN-102822165-B Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2015-02-25 CN disclosed
US-20130324518-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2013-12-05 US disclosed
US-8518972-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-08-27 US disclosed
EP-2536706-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2012-12-26 EP disclosed
CN-102822165-A Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORP 2012-12-12 CN disclosed
WO-2011100380-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2011-08-18 WO disclosed
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CELGENE CORPORATION 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324518-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-20160159768-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-10669257-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-20200231567-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885
US-20190135780-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 ALDH1A1 1096/4885MEN1 3301/4885KMT2A 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.